News & Updates

Pulmonary arterial hypertension outcomes better with early therapy augmentation with selexipag

04 Oct 2024 by

In the treatment of patients with pulmonary arterial hypertension, adding selexipag as a third medication sooner rather than later is crucial to help prevent hospitalization and disease progression, as suggested in an emulated target trial.

Pulmonary arterial hypertension outcomes better with early therapy augmentation with selexipag

04 Oct 2024

Which factors predict survival in lenvatinib-treated RR-DTC?

04 Oct 2024

Patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC) with good ECOG* performance status and radioactive iodine (RAI) avidity benefit the most from treatment with lenvatinib, a study has shown. Moreover, the only independent predictor of survival after treatment initiation is objective response.

Which factors predict survival in lenvatinib-treated RR-DTC?

04 Oct 2024

BP-lowering medication deprescribing helps preserve cognitive function in nursing home residents

04 Oct 2024

Older nursing home residents who have been deprescribed antihypertensive medications show slower cognitive decline when compared with residents who maintain a stable antihypertensive regimen, as shown in a study.

BP-lowering medication deprescribing helps preserve cognitive function in nursing home residents

04 Oct 2024

Mirtazapine disappoints in BETTER-B trial

04 Oct 2024 by

The investigational antidepressant mirtazapine appears no better than placebo at alleviating severe, intractable breathlessness from chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD), as shown in the phase III BETTER-B trial.

Mirtazapine disappoints in BETTER-B trial

04 Oct 2024

Ever considered interrupting the β-blocker in a stable post-MI patient? ABYSS suggests don’t

04 Oct 2024 by

In stable post-MI patients without a reduced EF who have been on long-term β-blockers, interrupting the β-blocker treatment instead of continuing it leads to more hospitalizations for CV reasons and does not improve QoL, as shown in the phase III ABYSS trial presented at ESC 2024

Ever considered interrupting the β-blocker in a stable post-MI patient? ABYSS suggests don’t

04 Oct 2024

Pharmacist-led two-dose cefepime protocol a boon for sepsis patients

03 Oct 2024

Implementing a pharmacist-driven protocol of second-dose cefepime results in a lower duration between second-dose antibiotics, days requiring vasopressors, and a slight decrease in length of hospital stay among adult patients with sepsis in the emergency department (ED), according to a study.

Pharmacist-led two-dose cefepime protocol a boon for sepsis patients

03 Oct 2024

Metoclopramide of no help in improving pneumonia, functional outcomes in select stroke patients

03 Oct 2024

For patients who have been placed on a nasogastric tube shortly after stroke onset, a 4-day treatment course of metoclopramide does not appear to have any effect on the incidence of pneumonia or functional outcomes, according to data from the PRECIOUS trial.

Metoclopramide of no help in improving pneumonia, functional outcomes in select stroke patients

03 Oct 2024

The FINEART of finerenone: A new option for HFmrEF/HFpEF?

03 Oct 2024 by

Full results of the phase III FINEARTS-HF trial have shown that finerenone cuts the risk of worsening heart failure (HF) events and cardiovascular (CV) death in symptomatic HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF).

The FINEART of finerenone: A new option for HFmrEF/HFpEF?

03 Oct 2024

Crisugabalin for postherpetic neuralgia scores high in phase III trial

02 Oct 2024 by

The oral calcium channel α2δ-1 subunit ligand crisugabalin appears to provide relief for patients with postherpetic neuralgia, significantly reducing average daily pain scores as compared with placebo, as shown in a phase III trial.

Crisugabalin for postherpetic neuralgia scores high in phase III trial

02 Oct 2024

Does azithromycin prolong QT Interval in ICU patients?

02 Oct 2024

Use of azithromycin among patients admitted to the intensive care unit (ICU) does not appear to contribute significantly to the increase in QTc interval, a study has shown.

Does azithromycin prolong QT Interval in ICU patients?

02 Oct 2024

News & Updates

Filter by Specialty:

Specialty:

Pulmonary arterial hypertension outcomes better with early therapy augmentation with selexipag

Pulmonary arterial hypertension outcomes better with early therapy augmentation with selexipag

Which factors predict survival in lenvatinib-treated RR-DTC?

Which factors predict survival in lenvatinib-treated RR-DTC?

BP-lowering medication deprescribing helps preserve cognitive function in nursing home residents

BP-lowering medication deprescribing helps preserve cognitive function in nursing home residents

Mirtazapine disappoints in BETTER-B trial

Mirtazapine disappoints in BETTER-B trial

Ever considered interrupting the β-blocker in a stable post-MI patient? ABYSS suggests don’t

Ever considered interrupting the β-blocker in a stable post-MI patient? ABYSS suggests don’t

Pharmacist-led two-dose cefepime protocol a boon for sepsis patients

Pharmacist-led two-dose cefepime protocol a boon for sepsis patients

Metoclopramide of no help in improving pneumonia, functional outcomes in select stroke patients

Metoclopramide of no help in improving pneumonia, functional outcomes in select stroke patients

The FINEART of finerenone: A new option for HFmrEF/HFpEF?

The FINEART of finerenone: A new option for HFmrEF/HFpEF?

Crisugabalin for postherpetic neuralgia scores high in phase III trial

Crisugabalin for postherpetic neuralgia scores high in phase III trial

Does azithromycin prolong QT Interval in ICU patients?

Does azithromycin prolong QT Interval in ICU patients?